To the Editor: It is not surprising that Dr
Lasser and colleagues1 found that serious
ADRs are commonly discovered after the FDA has approved a new drug. The inherent
limitations of clinical trials (ie, relatively small size, generally narrow
study populations, narrow indication, and relatively short duration) significantly
affect their ability to detect rare, serious ADRs,2
and are the raison d'être for postmarketing medical product monitoring.
Similarly, it is known that a striking (at times, exponential) increase in
patient exposure can occur once a drug comes to market. Patient populations
(perhaps even an entire sex) who comprised little or none of the premarketing
study group may undergo treatment with the drug.3
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Purchase Online Access to this article for 24 hours
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 1
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
and access these and other features:
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.